ArticleRMD open2023

Leflunomide/hydroxychloroquine combination therapy targets type I IFN-associated proteins in patients with Sjögren's syndrome that show potential to predict and monitor clinical response.

Safae Hamkour et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.